Nogo presence is inversely associated with shifts in cortical microglial morphology following experimental diffuse

Jenna M Ziebell1, Helen Ray-Jones2, Jonathan Lifshitz3

  • 1Barrow Neurological Institute at Phoenix Children's Hospital, Phoenix, AZ, USA; Department of Child Health, University of Arizona College of Medicine - Phoenix, Phoenix, AZ, USA.

Neuroscience
|July 25, 2017
PubMed

Insights

Diffuse traumatic brain injury (TBI) causes inflammation and myelin damage. The Nogo-66 receptor antagonist peptide NEP(1-40) was tested and showed potential to alter microglia activation and morphology following TBI.

Area of Science:

  • Neuroscience
  • Immunology
  • Pathology

Background:

  • Diffuse traumatic brain injury (TBI) triggers secondary pathologies, including neuroinflammation and demyelination.
  • Activated microglia exhibit diverse morphologies and functions, influenced by myelin debris like Nogo.

Purpose of the Study:

  • To investigate the relationship between inflammation and reduced myelin antigenicity post-TBI.
  • To test the hypothesis that NEP(1-40) can reverse TBI-induced microglia morphology shifts by mitigating myelin-based inhibition.

Main Methods:

  • Adult male rats underwent diffuse TBI or sham procedures.
  • Immunohistochemical staining analyzed myelin antigens (MBP, CNPase), microglia morphology (Iba1), Nogo receptor, and Nogo in the sensory cortex (S1BF) at various time points.
  • NEP(1-40) or vehicle was administered to assess its effect on microglia morphology post-injury.

Main Results:

  • TBI led to a transient reduction in myelin antigenicity and white matter disorganization at 1 day post-injury.
  • Microglia morphology shifted from ramified to activated states (hyper-ramified, fully activated, rod) as early as 2 hours post-TBI and persisted for at least 21 days.
  • NEP(1-40) administration shifted microglia distributions towards rod and macrophage-like morphologies compared to vehicle, though differences diminished by 7 days post-injury.

Conclusions:

  • This study links white matter damage and inflammation as co-occurring secondary pathologies after diffuse TBI.
  • These interacting pathologies may contribute to disrupted neuronal circuits and neurological deficits.
  • Further research is needed to fully elucidate the therapeutic potential of targeting myelin-based inhibition in TBI.

Related Concept Videos